Improving Outcomes Of Severe Bacterial Infections In Northern Australia
Funder
National Health and Medical Research Council
Funding Amount
$217,274.00
Summary
Severe infections such as pneumonia can cause failure of vital organs (severe sepsis) and subsequent death. 30-40% of people who develop severe sepsis die, even with the best modern therapies. Sepsis is five times more common in northern Australia than elsewhere. In this program of research, we plan to test new therapies for sepsis; to determine the causes of and risk factors for severe pneumonia in northern Australia; and to use this information to inform new guidelines for the management of se ....Severe infections such as pneumonia can cause failure of vital organs (severe sepsis) and subsequent death. 30-40% of people who develop severe sepsis die, even with the best modern therapies. Sepsis is five times more common in northern Australia than elsewhere. In this program of research, we plan to test new therapies for sepsis; to determine the causes of and risk factors for severe pneumonia in northern Australia; and to use this information to inform new guidelines for the management of sepsis and pneumonia in northern Australia.Read moreRead less
The Arthroplasty Surgical Antibiotic Prophylaxis (ASAP) Study
Funder
National Health and Medical Research Council
Funding Amount
$3,509,985.00
Summary
The demand for total joint replacement surgery will double over the next decade. Infection involving the surgical wound is a devastating complication of this surgery. Half of all infections are due to methicillin resistant Staphylococcus (such as MRSA) and Enterococcus. This multicentre randomised controlled trial aims to investigate whether the addition of vancomycin at the time of surgery reduces the incidence of surgical wound infections; is safe and is cost-effective.
Randomised Trial To Determine The Safety And Efficacy Of Early Vs Deferred Treatment Of HIV
Funder
National Health and Medical Research Council
Funding Amount
$1,070,331.00
Summary
Treatments for HIV represent a miraculous achievement of medical research. Global use of antiretroviral drugs has prevented substantial morbidity and mortality. However, it is unclear if these drugs should be used in people who are HIV positive with early HIV disease but no clinical symptoms. The START trial will result in a precise estimate of the risk-benefit for earlier versus later use of these treatments. It will immediately affect treatment guidelines around the world and inform future res ....Treatments for HIV represent a miraculous achievement of medical research. Global use of antiretroviral drugs has prevented substantial morbidity and mortality. However, it is unclear if these drugs should be used in people who are HIV positive with early HIV disease but no clinical symptoms. The START trial will result in a precise estimate of the risk-benefit for earlier versus later use of these treatments. It will immediately affect treatment guidelines around the world and inform future research for many years to come.Read moreRead less
A Randomised Trial To Compare Dolutegravir+darunavir/r Versus Recommended Standard Of Care Antiretroviral Regimens In Patients With HIV Infection Who Have Failed Recommended First Line Therapy
Funder
National Health and Medical Research Council
Funding Amount
$2,323,209.00
Summary
Public sector programs for provision of antiretroviral drugs in developing countries need regimens of therapy that are safe, effective and simple to administer. The evidence base to support first line therapy is strong. This contrasts with a relative paucity of evidence for second regimens of therapy once first line effectiveness has been lost. This trial will address that evidential deficit and support evidence-based recommendations for global health.